Biosimilar Boom in China Heralded By First Approval
Executive Summary
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
You may also be interested in...
Changes Encourage Celltrion And Nan Fung To Bet On China Biosimilars Opportunity
Despite increasing competition, Celltrion has leapt into China's growing biosimilar market through a joint venture with Nan Fung, and another draw could lie in the biologics contract manufacturing potential in the country’s developing Greater Bay Area.
R&D Executives Seek China Role In Clinical Development
What excites R&D heads and executives when it comes to China? Regulatory reforms, certainly, but emerging technologies including AI could position China for a bigger play, going by discussions at a recent forum that saw AstraZeneca, Sanofi, Beigene and Jiangsu Hengrui executives debate future biopharma development in China.
China - The Next Promised Land For Korean Biosimilars?
Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market for their biosimilars amid the Chinese government's increasing policy support for biologics and generics, and rising competition elsewhere. Part of their tailored entry approach includes striking deals with local partners.